Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov

Featuring an interview with Dr Douglas W Sborov, including the following topics:

DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)
Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)
Prevention and management of ophthalmic events related to treatment with belamaf (21:27)
Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)
Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)
Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)